DUBLIN–(BUSINESS WIRE)–The “Respiratory Syncytial Virus Infections – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This “Respiratory syncytial virus infections – Pipeline Insight, 2021” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Respiratory syncytial virus infections pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The companies and academics are working to assess challenges and seek opportunities that could influence Respiratory syncytial virus infections R&D. The therapies under development are focused on novel approaches to treat/improve Respiratory syncytial virus infections.
Respiratory syncytial virus infections Emerging Drugs Chapters
This segment of the Respiratory syncytial virus infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Respiratory syncytial virus infections Emerging Drugs
GSK3844766A: GlaxoSmithKline
This candidate vaccine contains a recombinant subunit pre-fusion RSV antigen (RSVPreF3) combined with GSK’s proprietary AS01 adjuvant, which is also used in GSK’s shingles vaccine. Currently, it is in phase III of development stage for the treatment of Respiratory syncytial virus infections.
Nirsevimab (MEDI-8897): MedImmune
MEDI8897 is a monoclonal antibody (mAb) for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV), the most prevalent cause of LRTI among infants and young children. Currently, it is in phase III of development stage.
Sisunatovir: ReViral
Sisunatovir is an orally administered fusion inhibitor designed to block RSV replication by inhibiting RSV F-mediated fusion of RSV with the host cell. Preclinical tests showed sisunatovir to have an excellent toxicity profile with an attractive therapeutic index. In Phase 1 clinical studies, sisunatovir showed excellent exposure with no serious adverse events being reported.
In 2018, results from a Phase 2a challenge study in healthy adult volunteers were reported in which sisunatovir produced statistically significant reductions in viral load and clinical symptoms. ReViral has initiated two international multicentre Phase 2 clinical studies of sisunatovir in pediatric and adult high-risk patient populations
Respiratory syncytial virus infections: Therapeutic Assessment
This segment of the report provides insights about the different Respiratory syncytial virus infections drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Respiratory syncytial virus infections
There are approx. 50+ key companies which are developing the therapies for Respiratory syncytial virus infections. The companies which have their Respiratory syncytial virus infections drug candidates in the most advanced stage, i.e. phase III include, GlaxoSmithKline.
Phases
This report covers around 50+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Respiratory syncytial virus infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Products have been categorized under various ROAs such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical.
Molecule Type
Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Respiratory syncytial virus infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Respiratory syncytial virus infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Respiratory syncytial virus infections drugs.
Respiratory syncytial virus infections Report Insights
Respiratory syncytial virus infections Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Respiratory syncytial virus infections Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs
Key Questions Answered
How many companies are developing Respiratory syncytial virus infections drugs?
How many Respiratory syncytial virus infections drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Respiratory syncytial virus infections?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Respiratory syncytial virus infections therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Respiratory syncytial virus infections and their status?
What are the key designations that have been granted to the emerging drugs?
Key Players
GlaxoSmithKline
MedImmune
ReViral
Pfizer
Sanofi
BioComo
IMV
Shionogi
Aridis Pharmaceuticals
ADMA Biologics
Enanta Pharmaceuticals
Merck Sharp & Dohme
Janssen Research & Development
Ark Biosciences
BlueWillow Biologics
Meissa Vaccines
Alios BioPharma
Codagenix
Advance Vaccine Laboratories
Bavarian Nordic
ModernaTX, Inc.
Virometix
Airway Therapeutics LLC
AlloVir Inc
Anima Biotech Inc
Aridis Pharmaceuticals Inc
Atea Pharmaceuticals Inc
Atriva Therapeutics
Calder Biosciences Inc
Cidara Therapeutics Inc
Clover Biopharmaceuticals
Curevac AG
Enyo Pharma SA
HanaVax Inc.
Icosavax Inc
IDBiologics Inc
Pneumagen Ltd
Riboscience LLC
Signia Therapeutics
Key Products
GSK3844766A
Nirsevimab (MEDI-8897)
Sisunatovir
RSV F protein vaccine
Novavax
Combination seasonal influenza RSV nanoparticle vaccine
NanoFlu/NVX CoV 2373/RSV
RSVpreF
SP 0125
BC-0004
GSK 3888550A
DPX RSV Vaccine
AR 201
ASCENIV
EDP 938
MK 1654
Rilematovir
GSK 3003891A
JNJ 64400141
Ziresovir
JNJ 64213175
MV-012-968
ALS-008176
CodaVax-RSV
BARS13
MVA-BN-RSV
mRNA-1345
V-306
ALVR106
AR-201
AT-889
ATR-002
IVX-121
RBS-3149
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/2kxuq
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900